DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the GRANULES INDIA LIMITED (GRANULES) share price today?

GRANULES INDIA LIMITED (GRANULES) is trading at ₹880.8 on the NSE, down 2.49% on the day. Source: DocStoX.

What is the PE ratio of GRANULES INDIA LIMITED?

GRANULES INDIA LIMITED has a price-to-earnings (PE) ratio of 36.7 in the Healthcare sector.

What is the market capitalisation of GRANULES INDIA LIMITED?

GRANULES INDIA LIMITED has a market capitalisation of approximately ₹21,843 crore.

GRANULES INDIA LIMITED

GRANULES·NSE·Healthcare

₹880.80▼ -22.45 (-2.49%)

Healthcare · Pharmaceuticals

A steady, established business

NIFTY 500NIFTY SMALLCAP 250

Day₹870.15

₹902.75

52W₹433

₹91094%

Open

₹902.75

High

₹902.75

Low

₹870.15

Prev Close

₹903.25

Volume

16.99L

VWAP

₹882.08

Snapshot

Key fundamentals

Market Cap

₹21,843 Cr

P/E Ratio

36.68Expensive

P/B Ratio

4.03

EPS

₹24.01

Book Value

₹205.00

ROE

13.70%Average

ROCE

15.00%Decent

Dividend Yield

0.20%

Debt / Equity

0.30Low

Face Value

₹1.00

52W High

₹910.00

52W Low

₹432.60

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

None moatHigh uncertainty

Fair value estimate

₹235

▼ 73.3%downside

Trading at ₹881 — 73% above our estimate

BearFair valueBull

₹200₹235₹333

/100

Business quality — Watch the fundamentals

Growth 21Profitability 47Efficiency 18Valuation 59

Plain English

Our view

A steady, established business
Low debt relative to equity
Fundamental red flags (Piotroski 1/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

36.7Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

13.7%Average

Above 15% is considered healthy for Indian equities

ROCE

15.0%Decent

Above 18% means capital is working hard

Debt/Eq

0.30Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹21,843 Cr

P/B

4.03

EPS

₹24.01

Div Yield

0.20%

What changed

Recent changes

Foreign investors+2.2% stake last quarter
Domestic institutions-0.9% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 36.7×

Growth

Steady

+6% rev CAGR

Profitability

Healthy

13.7% ROE

Financial health

Rock solid

D/E 0.30

Momentum

N/A

No technicals

Today

Trading activity

Delivery %62.3%

Turnover₹14988.85L Cr

Trades56,307

VWAP₹882.08

Face value₹1.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+6.0%

+10.6%

10Y

+14.7%

Profit

+4.8%

+1.6%

10Y

+17.1%

EPS

+4.0%

+1.6%

10Y

+15.5%

Profile

Cons

The company has delivered a poor sales growth of 10.6% over past five years.
Company has a low return on equity of 13.7% over last 3 years.
Company might be capitalizing the interest cost
Dividend payout has been low at 7.84% of profits over last 3 years
Promoter holding has decreased over last 3 years: -4.00%

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 2.19 pts; domestic institutions reduced 0.90 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

38%

Promoter

Promoters

38.0%-0.01

Public

28.4%-1.31

FII / FPI

17.5%+2.19

DII

16.1%-0.90

Total shareholders

1,69,422+9,136 QoQ

Quarterly trend

Ownership over time

Q1 FY27

Promoter38.01%

FII17.50%

DII16.11%

Public28.36%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions